DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 199 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $643,264 | -29.0% | 31,181 | +1.5% | 0.01% | -28.6% |
| Q2 2023 | $906,311 | +42.8% | 30,712 | +11.5% | 0.01% | +16.7% |
| Q1 2023 | $634,660 | -6.3% | 27,546 | +13.1% | 0.01% | -14.3% |
| Q4 2022 | $677,563 | -5.6% | 24,364 | +4.2% | 0.01% | 0.0% |
| Q3 2022 | $718,000 | +5.3% | 23,388 | +1.0% | 0.01% | 0.0% |
| Q2 2022 | $682,000 | -1.2% | 23,167 | +8.0% | 0.01% | +16.7% |
| Q1 2022 | $690,000 | -27.3% | 21,458 | +0.8% | 0.01% | -14.3% |
| Q4 2021 | $949,000 | -12.4% | 21,280 | -0.8% | 0.01% | -22.2% |
| Q3 2021 | $1,083,000 | -34.8% | 21,458 | +1.3% | 0.01% | -35.7% |
| Q2 2021 | $1,662,000 | +28.2% | 21,188 | -6.6% | 0.01% | +27.3% |
| Q1 2021 | $1,296,000 | -31.0% | 22,690 | +1.2% | 0.01% | -35.3% |
| Q4 2020 | $1,878,000 | +119.4% | 22,420 | -6.2% | 0.02% | +88.9% |
| Q3 2020 | $856,000 | +98.1% | 23,904 | +33.9% | 0.01% | +50.0% |
| Q2 2020 | $432,000 | +68.1% | 17,846 | +21.8% | 0.01% | +50.0% |
| Q1 2020 | $257,000 | – | 14,654 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |